1. Home
  2. RVT vs IMNM Comparison

RVT vs IMNM Comparison

Compare RVT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Value Trust Inc.

RVT

Royce Value Trust Inc.

HOLD

Current Price

$17.35

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.66

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVT
IMNM
Founded
1986
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RVT
IMNM
Price
$17.35
$22.66
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.22
AVG Volume (30 Days)
243.4K
2.5M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
7.32%
N/A
EPS Growth
N/A
N/A
EPS
2.95
N/A
Revenue
N/A
$9,679,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.53
P/E Ratio
$4.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.85
$5.15
52 Week High
$14.93
$25.30

Technical Indicators

Market Signals
Indicator
RVT
IMNM
Relative Strength Index (RSI) 73.97 60.67
Support Level $16.95 $20.05
Resistance Level $17.20 $22.01
Average True Range (ATR) 0.20 1.28
MACD 0.09 0.04
Stochastic Oscillator 99.28 82.00

Price Performance

Historical Comparison
RVT
IMNM

About RVT Royce Value Trust Inc.

Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: